Free shipping on all orders over $ 500

Vanucizumab

Cat. No. M24682
Vanucizumab Structure
Synonym:

Anti-Human VEGFA Recombinant Antibody RO5520985

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.

Chemical Information
CAS Number 1448221-05-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Digna Parmar, et al. Eur J Pharmacol. Angiopoietin inhibitors: A review on targeting tumor angiogenesis

[2] Florian Heil, et al. Transl Oncol. Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

[3] Johanna C Bendell, et al. Oncologist. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

[4] Manuel Hidalgo, et al. Clin Cancer Res. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

[5] Christian Klein, et al. MAbs. The use of CrossMAb technology for the generation of bi- and multispecific antibodies

Related VEGFR/PDGFR Products
Pegaptanib Sodium

Pegaptanib Sodium is an RNA aptamer targeting vascular endothelial growth factor (VEGF)-165, a molecule of oligonucleotides chemically linked to polyethylene glycol (PEG), which can be used in studies related to neovascular age-related macular degeneration (AMD).

Jolkinolide A

Jolkinolide A is a diterpenoid, which exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells.

N-(p-Coumaroyl) Serotonin

N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on phosphorylation of PDGF receptor and Ca2+ release from sarcoplasmic reticulum. N-(p-Coumaroyl) Serotonin ameliorates atherosclerosis and distensibility of the aortic wall in vivo and is usually used for the atherosclerosis research.

VEGFR-2-IN-5 hydrochloride 

VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor.

AMG-Tie2-1 

AMG-Tie2-1 is an inhibitor of tunica interna endothelial cell kinase 2 (Tie2) with an IC50 of 1 nM. AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50 of 3 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vanucizumab, Anti-Human VEGFA Recombinant Antibody RO5520985 supplier, VEGFR/PDGFR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.